Metoprolol Succinate Tablet, Film Coated, Extended Release
Product Images NDC 72162-1858

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 72162-1858). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621858)

Label (Lbl721621858)
Label for Metoprolol Succinate Extended-Release Tablets, USP 100 mg, oral film-coated tablets. The label indicates 100 tablets per container and includes warnings, storage instructions, and dispensing cautions. The product is relabeled by Bryant Ranch Prepack, Burbank, CA, and manufactured by Alkem Laboratories Ltd. NDC 72162-1858-1 is shown with barcodes.*
FDA Label Image

Metoprolol-structure (Metoprolol Structure)

Metoprolol-structure (Metoprolol Structure)
Chemical structure of Metoprolol Succinate, showing two metoprolol moieties and a succinate moiety, depicting the molecular arrangement of atoms and bonds in this extended release tablet ingredient.*
FDA Label Image

Metoprolol-table1a (Metoprolol Table1a)

Metoprolol-table1a (Metoprolol Table1a)
A forest plot titled "Results for Subgroups in MERIT-HF" displaying relative risk and 95% confidence intervals for three outcomes: Total Mortality, Total Mortality or All-Cause Hospitalization, and Total Mortality or Hospitalization for Heart Failure. Subgroups include US, Non-US, NYHA classes II-IV, ejection fractions, ischemic and non-ischemic etiology, sex, race, myocardial infarction history, diabetes mellitus, hypertension, and heart rate categories. Risk favored either Metoprolol Succinate Extended-Release Tablets or Placebo across subgroups, with axes spanning from 0 to 2 relative risk.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.